专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009134371A3 COMPOSITE LACRIMAL INSERT AND RELATED METHODS 审中-公开
标题翻译：复合材料插入和相关方法
公开(公告)号：WO2009134371A3
公开(公告)日：2010-08-12
申请号：PCT/US2009002611
申请日：2009-04-29
申请人： QLT PLUG DELIVERY INC , SIM SYLVIE , JAIN RACHNA , FARINAS KATHLEEN
发明人： SIM SYLVIE , JAIN RACHNA , FARINAS KATHLEEN
IPC分类号： A61K9/20
CPC分类号： A61L31/06 , A61F9/0008 , A61F9/0017 , A61K9/0051 , A61K47/34 , A61L31/145 , A61L31/16
摘要： Lacrimal implants, methods of making lacrimal implants, and methods of treating ocular, respiration or other diseases or disorders using lacrimal implants are disclosed.
摘要翻译：公开了泪液植入物，制造泪腺植入物的方法以及使用泪液植入物治疗眼睛，呼吸或其它疾病或障碍的方法。

2. 发明申请

WO2009035562A3 DRUG CORES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS 审中-公开
标题翻译：药物核心用于持续释放治疗药物
公开(公告)号：WO2009035562A3
公开(公告)日：2009-07-02
申请号：PCT/US2008010487
申请日：2008-09-05
申请人： QLT PLUG DELIVERY INC , UTKHEDE DEEPANK , SHIMIZU ROBERT W , JAIN RACHNA , BOYD STEPHEN , GIFFORD HANSON S , DE JUAN JR EUGENE , REICH CARY J
发明人： UTKHEDE DEEPANK , SHIMIZU ROBERT W , JAIN RACHNA , BOYD STEPHEN , GIFFORD HANSON S , DE JUAN JR EUGENE , REICH CARY J
IPC分类号： A61K9/00 , A61F2/02 , A61F9/00 , A61M5/14
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/00772 , A61F2230/0069 , A61F2250/0067 , A61K31/5575 , A61K47/34 , A61L27/54 , A61L2300/41 , A61L2300/602 , A61L2300/802
摘要： A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.
摘要翻译：可以通过将包含治疗剂和基质前体的液体混合物注射到鞘体中来制造固体药心插入物。注射可以在低于环境温度下进行。混合物固化形成固体药物基质核心。治疗剂在约室温下可以是液体，其在基质材料中形成液滴分散体。例如通过切割管暴露固体药物核心的表面，并且当植入患者体内时，固体药物核心的暴露表面释放治疗量的治疗剂。在一些实施方案中，插入体抑制治疗剂的释放，例如用治疗剂基本上不可渗透的材料，使得治疗量通过暴露的表面释放，由此避免治疗剂释放到非靶组织。

3. 发明申请

WO2009105178A3 LACRIMAL IMPLANTS AND RELATED METHODS 审中-公开
标题翻译： LACRIMAL植入物及相关方法
公开(公告)号：WO2009105178A3
公开(公告)日：2010-06-03
申请号：PCT/US2009000963
申请日：2009-02-17
申请人： QLT PLUG DELIVERY INC , JAIN RACHNA , SHIMIZU ROBERT W
发明人： JAIN RACHNA , SHIMIZU ROBERT W
IPC分类号： A61F9/007
CPC分类号： A61F9/0017 , A61B17/12022 , A61F9/00772 , A61F9/00781 , A61F2210/0061 , A61K9/0051 , A61M29/02 , A61M31/00 , A61M31/002 , A61M2207/00 , A61M2210/0612
摘要： Lacrimal implants (300) providing secure retention within the lacrimal punctum of an eye are described. The lacrimal implants can comprise a implant body (302) configured for at least partial insertion through the lacrimal punctum and into a lacrimal canaliculus. The implant body can include a deformable retention structure (308) that can be configured to substantially encapsulate an expandable retention element. In some examples, the expandable retention element can include a fluid absorbing material, which can be exposed to fluid such as via a fluid permeable retainer or a fluid permeable aperture (320). As the fluid absorbing material retains fluid (i.e., upon acceptance of fluid into the retention structure), its size increases and its shape can change to urge one or more portions of the retention structure outward, such as against a wall of the lacrimal canaliculus, thereby securely retaining the lacrimal implant within the punctum.
摘要翻译：描述了在泪液泪点内提供牢固保留的泪液植入物（300）。泪液植入物可以包括植入物主体（302），其被构造成用于至少部分插入通过泪点并进入泪小管。植入物主体可以包括可变形的保持结构（308），其可被配置为基本上包封可扩张的保留元件。在一些示例中，可扩张保持元件可以包括流体吸收材料，其可以暴露于流体，例如经由流体可渗透保持器或流体可渗透孔（320）。当流体吸收材料保留流体（即，在将流体接受到保持结构中时），其尺寸增加并且其形状可以改变以将保留结构的一个或多个部分向外推动，例如抵靠泪小管的壁，从而将泪道植入物牢固地保持在泪点内。

4. 发明申请

WO2007131193A3 MAIN CHAIN ACID-DEGRADABLE POLYMERS FOR THE DELIVERY OF BIOACTIVE MATERIALS 审中-公开
标题翻译：用于输送生物材料的主链酸可降解聚合物
公开(公告)号：WO2007131193A3
公开(公告)日：2009-04-09
申请号：PCT/US2007068284
申请日：2007-05-04
申请人： UNIV CALIFORNIA , FRECHET JEAN M J , STANDLEY STEPHANY M , JAIN RACHNA , LEE CAMERON C
发明人： FRECHET JEAN M J , STANDLEY STEPHANY M , JAIN RACHNA , LEE CAMERON C
IPC分类号： A61K9/14
CPC分类号： A61K31/787 , A61K9/1641 , A61K47/34
摘要： Novel main chain acid degradable polymer backbones and drug delivery systems comprised of materials capable of delivering bioactive materials to cells for use as vaccines or other therapeutic agents are described. The polymers are synthesized using monomers that contain acid-degradable linkages cleavable under mild acidic conditions. The main chain of the resulting polymers readily degrade into many small molecules at low pH, but remain relatively stable and intact at physiological pH. The new materials have the common characteristic of being able to degrade by acid hydrolysis under conditions commonly found within the endosomal or lysosomal compartments of cells thereby releasing their payload within the cell. The materials can also be used for the delivery of therapeutics to the acidic regions of tumors and other sites of inflammation.
摘要翻译：描述了由能够将生物活性物质递送至用作疫苗或其它治疗剂的细胞的材料组成的新型主链酸可降解聚合物主链和药物递送系统。使用含有酸可降解键的单体在温和的酸性条件下可裂解来合成聚合物。所得聚合物的主链在低pH下容易降解成许多小分子，但在生理pH下保持相对稳定和完整。新材料具有在细胞的内体或溶酶体区室内通常发现的条件下能够通过酸水解降解的共同特征，从而释放其在细胞内的有效载荷。这些材料也可以用于将治疗剂递送到肿瘤和其它炎症部位的酸性区域。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式